Kalytera Therapeutics Inc has entered into a binding letter of intent (LOI) to acquire Talent Biotechs Ltd, an Israeli-based developer of proprietary cannabidiol (CBD) therapeutics.
Currently, Talent is advancing a phase 2 clinical program examining the use of CBD to prevent and treat Graft versus Host Disease (GvHD), according to a press release.
GvHD is a multisystem disorder that arises following stem cell or bone barrow transplants. It occurs when transplanted donor cells recognize the transplant recipient as foreign, and attacks the patient’s organs.
Under the LOI transaction terms, Kalytera has made a non-refundable payment of $1 million to Talent. According to the release, the acquisition is subject to final due diligence by Kalytera, and other customary closing conditions.
In May 2015, results from a phase 2a clinical study investigating the use of CBD for the prevention of GvHD were published, along with promising initial results. The results of the trial showed that CBD